Takeda Pharmaceutical Co Ltd (TAK)
U.S. FDA Accepts Takedas Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohns Disease
U.S. FDA Accepts Takedas Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohns Disease
📊 **NEUTRAL** • Medium confidence analysis (70%) • Weak signals • Minimal impact expected **Sentiment:** Neutral (50%) **Content type:** General